Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis  Anthony T. Reder, Joel F. Oger, Ludwig Kappos, Paul O’Connor, Mark Rametta  Multiple Sclerosis and Related Disorders  Volume 3, Issue 3, Pages 294-302 (May 2014) DOI: 10.1016/j.msard.2013.11.005 Copyright © 2013 Elsevier B.V. Terms and Conditions

Fig. 1 Incidence of flu-like symptoms (FLS) during the first year and after the first year in BENEFIT and BEYOND. Rates of flu-like symptoms (FLS) in BENEFIT and BEYOND. Rates of FLS declined after the first year on interferon β-1b in both studies (Kappos et al., 2006; Reder et al., 2010b). Multiple Sclerosis and Related Disorders 2014 3, 294-302DOI: (10.1016/j.msard.2013.11.005) Copyright © 2013 Elsevier B.V. Terms and Conditions

Fig. 2 Incidence of injection site reactions (ISR) during the first year and after the first year in BENEFIT and BEYOND. Rates of injection site reactions (ISR) in BENEFIT and BEYOND. As with FLS, rates of ISR tended to decline after the first year on interferon β-1b (Kappos et al., 2006; Reder et al., 2010b). Multiple Sclerosis and Related Disorders 2014 3, 294-302DOI: (10.1016/j.msard.2013.11.005) Copyright © 2013 Elsevier B.V. Terms and Conditions

Fig. 3 Survival from randomization to death in patients on interferon β-1b 250μg vs. placebo (A) and 50μg vs. placebo (B). Kaplan–Meier survival curves from the time of randomization in the pivotal trial of interferon β-1b to death. Patients originally randomized to placebo had a significantly higher rate of all-cause mortality than either dose of interferon beta-1b (Goodin et al., 2012b). Adapted with permission from Lippincott Williams and Wilkins/Wolters Kluwer Health: Goodin et al. (2012b), copyright 2012. Multiple Sclerosis and Related Disorders 2014 3, 294-302DOI: (10.1016/j.msard.2013.11.005) Copyright © 2013 Elsevier B.V. Terms and Conditions